Waters Buys MOBILion to Add Ion Mobility for Proteomics Research

Waters Corporation announced on November 3, 2026 (WAT ) that it had acquired MOBILion Systems, adding high-resolution ion-mobility separation to its mass-spectrometry portfolio and broadening its entry into proteomics. Financial terms were not disclosed.

MOBILion’s SLIM technology, short for Structures for Lossless Ion Manipulations, separates molecules by size, shape and charge in milliseconds. It resolves molecular differences that are difficult to distinguish using liquid chromatography and mass spectrometry alone. Waters is pairing that capability with the speed and resolution of its Xevo MRT MS. The company says the combination enables superior bottom-up analysis of complex proteomes compared with LC-MS alone and is expected to increase proteome coverage, sensitivity and throughput for complex biological samples.

Commercial Rationale in Proteomics

Waters estimates that LC-MS proteomics represents a $2 billion total addressable market growing at a high-single-digit rate. Its estimate is based on internal analysis incorporating consulting data, industry reports and market research. That market estimate supplies the commercial context for adding separation capability to Waters’ existing instrument portfolio as it expands in proteomics.

Chief Executive Udit Batra described the acquisition as an advantage that would define Waters’ leadership first in research and, over time, in the clinic. MOBILion’s team brings deep expertise in developing and advancing the technology, adding specialist knowledge alongside the SLIM platform.

“SLIM was built to see what other separations miss,” said MOBILion CEO Melissa Sherman. She described Waters’ multi-reflecting time-of-flight technology as complementary and said combining it with high-resolution ion mobility could extend SLIM’s impact from leading research laboratories into routine testing worldwide.

AI-Enabled Research Workflows

AI-enabled research is a central part of the research-market push. Waters expects SLIM-enabled technology to support large-cohort studies and high-throughput generation of the high-quality data required by foundation and frontier AI models.

Waters AI Link brings Anthropic’s Model Context Protocol to waters_connect Software, while Waters participates in Anthropic’s Model Hardware Standard research program. Those capabilities support lab-in-the-loop experimentation, in which AI agents help design experiments and autonomously direct instrument operation. The acquisition therefore connects the production of proteomics data with software and instrument workflows intended to automate parts of the research process.

A Route From Discovery to Clinical Testing

Waters says the Xevo TQ Absolute XR tandem quadrupole mass spectrometer creates a path from biomarker discovery to targeted biomarker verification and validation in clinical-trial cohorts on a single platform. Workflows in the waters_connect Platform support method transfer from discovery into development, connecting the research and targeted-assay stages.

Beyond clinical-trial validation, Waters’ installed base of mass spectrometers in clinical laboratories provides a foundation for translating validated protein biomarkers into routine blood-based tests. The company sees a longer-term opportunity to expand test menus through multiplex diagnostic workflows for Multi-Cancer Early Detection and Minimal Residual Disease monitoring. Those applications remain future opportunities rather than outcomes already delivered by the acquisition.

The deal gives Waters a separation technology, a specialist team and a route from research instruments toward targeted assays. Its nearer-term research case rests on delivering the expected gains in proteome coverage and throughput. The larger diagnostics opportunity depends on a later step: protein biomarkers must be verified and validated before Waters’ installed clinical base can support their translation into routine blood-based tests.